Clinical characteristics and smoking cessation: An analysis of sex and depressive disorders differences

Addictive Disorders and their Treatment

Volumn 12, Issue 3, 2013, Pages 158-165

  Nunes, Sandra Odebrecht Vargas ^a   Pizzo De Castro, Márcia Regina ^a   Odebrecht Vargas, Heber ^a   Mendonça Vargas, Mateus ^a   Bueno Rezende MacHado, Regina Celia ^a   Batista Fonseca, Inês Cristina ^a   Dodd, Seetal ^b,c   Berk, Michael ^b,c,d  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b DEAKIN UNIVERSITY   (Australia)

^c BARWON HEALTH   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COGNITIVE THERAPY; DENSITY; DEPRESSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SEX DIFFERENCE; SMOKING CESSATION; WEIGHT GAIN;

EID: 84883455602     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/ADT.0b013e31827a63ff     Document Type: Article

References (31)

1. Ziedonis D, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res. 2008;10:1691-1715.
2. Dani J, Balfour D. Historical and current perspective on tobacco use and nicotine addiction. Trends Neurosci. 2011;34:383-392.
3. D'Souza M, Markou A. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sci Clin Pract. 2011;6:4-16.
4. Danovitch I. The clinical assessment and treatment of nicotine dependence. Focus. 2011;9:15-24.
5. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther. 2008;83:531-541.
6. Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362:2295-2303.
7. Simons L, Giorgio T. Characteristics of substance abusing men and women entering a drug treatment program: An exploration of sex differences. Addict Disord Treat. 2008;7:15-23.
8. Dome P, Lazary J, Kalapos MP, et al. Smoking, nicotine and neuropsychiatric disorders. Neurosci Biobehav Rev. 2010;34:295-342.
9. Nunes SOV, Vargas HO, Brum J, et al. A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tob Res. 2012;14: 540-546.
10. Dowlati Y, Herrmann N, Swardfager W, et al. A metaanalysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-457.
11. Yanbaeva D, Dentener M, Creutzberg E, et al. Systemic effects of smoking. Chest. 2007;135: 1557-1566.
12. Berk M, Ng F, Dean O, et al. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci. 2008;29:349-351.
13. Rytilä P, Rehn T, Ilumets H, et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir Res. 2006;69:1-10.
14. Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde 2004;Portaria SAS/MS 442/04 de 13 de agosto de 2004. Aprova o Plano de Implantação da Abordagem e Tratamento do Tabagismo no SUS. D.O.U n 158 17/08/2004. Bras?́lia, DF. Available at: http://dtr2001.saude.gov.br/sas/PORTARIAS/Port2004/PT-442.htm. Accessed June 20, 2012.
15. Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest. 2000; 117:758-763.
16. World Health Organization (WHO) 1993;The ICD-10 Classification of Mental and Behavioural Disorders, Diagnostic criteria for research. Available at: http://www.who.int/classifications/icd/en/GRNBOOK.pdf. Accessed June 20, 2012.
17. Fagerström K. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3: 235-241.
18. Fagerström KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerström tolerance questionnaire. J Behav Med. 1989;12:159-182.
19. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict. 1991;86:1119-1127.
20. Pomerleau CS, Carton SM, LutzkeML, et al. Reliability of the Fagerstrom tolerance questionnaire and the Fagerstrom test for nicotine dependence. Addict Behav. 1994;19:33-39.
21. Carmo JT, Pueyo AA. Adaptation into portuguese for the Fagerström test for nicotine dependence (FTND) to evaluate the dependence and tolerance for nicotine in brazilian smokers. Rev Bras Med. 2002;59:(1/2):73-80.
22. World Health Organization (WHO). The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction. 2002;97:1183-1194.
23. Ranney L, Melvin C, Lux L, et al. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med. 2006;145:845-856.
24. Castro MRP, Matsuo T, Nunes SOV. Characteristics of smokers in smoking cessation interventions: an analysis of sex differences. Addict Disord Treat. 2010;9:135-142.
25. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service; 2008.
26. Lee MH, Ahn SV, Hur NW, et al. Gender differences in the association between smoking and dyslipidemia: 2005 Korean National Health and Nutrition Examination Survey. Clin Chim Acta. 2011;412:(17/18): 1600-1605.
27. Reichert J, Araújo AJ, Gonçalves CMC, et al. Smoking cessation guidelines 2008. J Bras Pneumol. 2008;30:845-880.
28. Brady KT, Randall C. Gender differences in substance use disorders. Psychiatr Clin North Am. 1999;22: 241-252.
29. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Can Med Assoc J. 2008;179:135-144.
30. Berk M, Copolov D, Dean O, et al. N-Acetyl Cysteine for depressive symptoms in bipolar disorder-A double-blind randomized placebo-controlled trial. Biol Psychiatry. 2008;64:468-475.
31. Maes M, Galecki P, Chang YS, et al. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the neurodegenerative process in the illness. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35: 676-692.